Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding

Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives are critical for therapeutic programs. Here, we identify 3 mutations (T307P, L309Q, and Q311R or “TLQ”) in the Fc region of human IgG1 which disrupt interaction with protein A while enhancing interaction w...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 7; no. 1; pp. 15521 - 11
Main Authors Zwolak, Adam, Leettola, Catherine N., Tam, Susan H., Goulet, Dennis R., Derebe, Mehabaw G., Pardinas, Jose R., Zheng, Songmao, Decker, Rose, Emmell, Eva, Chiu, Mark L.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 14.11.2017
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives are critical for therapeutic programs. Here, we identify 3 mutations (T307P, L309Q, and Q311R or “TLQ”) in the Fc region of human IgG1 which disrupt interaction with protein A while enhancing interaction with FcRn. The mutations are shown to incrementally alter the pH at which a mAb elutes from protein A affinity resin. A BsAb comprised of a TLQ mutant and a wild-type IgG1 can be efficiently separated from contaminating parental mAbs by differential protein A elution starting from either a) purified parental mAbs, b) in-supernatant crossed parental mAbs, or c) co-transfected mAbs. We show that the Q311R mutation confers enhanced FcRn interaction in vitro , and Abs harboring either the Q311R or TLQ mutations have serum half-lives as long as wild-type human IgG1. The mutant Abs have normal thermal stability and Fcγ receptor interactions. Together, the results lead to a method for high-throughput generation of BsAbs suitable for in vivo studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-017-15748-0